Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/18/2025

Management of Hypertension and Coronary Artery Disease with Amlodipine

Introduction to Amlodipine Therapy

  • Dihydropyridine calcium channel blockers like amlodipine are considered appropriate drugs of choice for patients with stable angina and coronary artery disease, according to the American Heart Association 1, 2
  • In patients with hypertension and stable coronary artery disease, dihydropyridine CCBs can be added to the basic regimen of β-blocker, ACE inhibitor, and thiazide diuretic if either angina or hypertension remains uncontrolled, as recommended by the American College of Cardiology 2
  • First-line therapy should include a β-blocker (especially with prior myocardial infarction), ACE inhibitor or ARB (particularly with prior myocardial infarction, left ventricular dysfunction, diabetes, or chronic kidney disease), and thiazide or thiazide-like diuretic, as suggested by the American Heart Association 2
  • If blood pressure remains uncontrolled, adding a long-acting dihydropyridine CCB like amlodipine at appropriate dosing (5-10mg once daily) is recommended by the American College of Cardiology 2

Blood Pressure Targets and Management

  • For patients with coronary artery disease, the target blood pressure is <140/90 mmHg (Class IIa; Level of Evidence B), according to the American Heart Association 4
  • A lower target (<130/80 mmHg) may be considered in some individuals with coronary artery disease, previous stroke, or coronary artery disease risk equivalents (Class IIb; Level of Evidence B), as recommended by the American College of Cardiology 4
  • Combining non-dihydropyridine CCBs with β-blockers should be used with caution due to increased risk of bradyarrhythmias and heart failure, as noted by the American Heart Association 2

Special Considerations in Patient Management

  • In patients with heart failure and reduced ejection fraction, non-dihydropyridine CCBs (verapamil and diltiazem) should be avoided, according to the American College of Cardiology 5
  • For patients with hypertension and heart failure with preserved ejection fraction, dihydropyridine CCBs may be effective to minimize symptoms, as suggested by the American Heart Association 5
  • In elderly patients, monitoring for orthostatic changes and avoiding excessively low diastolic blood pressure (<65 mmHg) is recommended by the American Geriatrics Society 6